Monocyte cyclooxygenase-2 overactivity: A new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors?

European Heart Journal

Volumn 26, Issue 2, 2005, Pages 153-158

  Beloqui, Oscar ^a   Páramo, José A ^b   Orbe, Josune ^b   Benito, Alberto ^a   Colina, Inmaculada ^a   Monasterio, Alberto ^b   Díez, Javier ^b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Atherosclerosis; Cardiovascular risk; Carotid ultrasonography; Cyclooxygenase; Inflammation

Indexed keywords

C REACTIVE PROTEIN; CYCLOOXYGENASE 2; FIBRINOGEN; LIPOPOLYSACCHARIDE; PROSTAGLANDIN; PROSTAGLANDIN E2; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE MARKER; DYSLIPIDEMIA; ECHOGRAPHY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTENSION; INFLAMMATION; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; OBESITY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SMOKING;

ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAROTID ARTERY DISEASES; CYCLOOXYGENASE 2; DINOPROSTONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MACROPHAGES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS;

EID: 14144253447     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi016     Document Type: Article

References (41)

1. Ross R. Atherosclerosis. An inflammatory disease. N Engl J Med 1999;340:115-126.
2. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-874.
3. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-1073.
4. Hinson RM, Willians JA, Shacter E. Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc Natl Acad Sci USA 1996;93:4885-4890.
5. Smith WL, Langebach R. Why there are two cyclooxygenase isozymes. J Clin Invest 2001;107:1491-1495.
6. Tanabe T, Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Lipid Mediat 2002;68-69: 95-114.
7. Baker CSR, Hall RJC, Evans TJ, Pomerance A, Macleaf J, Creminon C, Yacoub M, Polak JM. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with indudble nitric oxide synthase and nitrotyrosine particularly in macrophages. Arteriosder Thromb Vasc Biol 1999;19:646-655.
8. Schönbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999;155:1281-1291.
9. Stemme V, Swedenborg J, Claesson HE, Hansson GK. Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries. Eur J Vasc Endovasc Surg 2000;20:146-152.
10. Mc Geer PL, Mc Geer E, Yasojima K. Expression of COX-1 and COX-2 mRNAs in atherosclerotic plaques. Exp Gerontol 2002;37:925-929.
11. Linton MF, Fazio S. Cyclooxygenase-2 and atherosclerosis. Curr Opin Lipidol 2002;13:497-504.
12. 2-dependent plaque instability. Circulation 2001;104:921-927.
13. Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, Marnett LJ, Morrow JD, Fazio S, Linton MF. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 2002;105:1816-1823.
14. Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobeli S, Cipollone F, Ganci A, Creminon C, Maclouf J. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide syntheses. J Pharmacol Exp Ther 1994;271:1705-1712.
15. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfason SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999;340:14-22.
16. Lekakis JP, Papamichael CM, Cimponeriu AT, Stamatelopoulos KS, Papaioannou TG, Kanakakis J, Alevizaki MK, Papaioannou A, Kalofoutis AT, Stamatelopoulos SF. Atherosclerotic changes of extracoronary arteries are associated with the extent of coronary atherosclerosis. Am J Cardiol 2000;85:949-952.
17. Greenland P, Smith SC, Grundy SM. Improving coronary heart disease assessment in asymptomatic people. Role of traditional risk factors and noninvasive cardiovascular tests. Circulation 2001;104:1863-1867.
18. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996;6:986-994.
19. Martinez-Vila E, Paramo JA, Beloqui O, Orbe J, Irimia P, Colina I, Benito A, Diez J. Independent association of fibrinogen with carotid intima-media thickness in asymptomatic subjects. Cerebrovasc Dis 2003;16:356-362.
20. Badawi AF, Habib SL, Mohammed MA, Abadi AA, Michael MS. Influence of cigarette smoking on prostaglandin synthesis and cyclooxygenase-2 gene expression in human urinary bladder cancer. Cancer Invest 2002;20:651-656.
21. Cosentino F, Eto M, De Paolis P, van der Loo B, Bachschmid M, Ullrich V, Kouroedov A, Delli Gatti C, Joch H, Volpe M, Luscher TF. High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation 2003;107:1017-1023.
22. Smith LH, Boutaud O, Breyer M, Morrow JD, Oates JA, Vaughan DE. Cyclooxygenase-2-dependent prostacyclin formation is regulated by low density lipoprotein cholesterol in vitro. Arterioscler Thromb Vasc Biol 2002;22:983-988.
23. Bermudez E, Rifai N, Buring J, Manson JE, Ridker PM. Interrelationships among circulating interleukin-6, C-reative protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 2002;22:1668-1673.
24. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, Lee L, Isakson P. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994;91:12013-12017.
25. Kuroda E, Yamashita U. Mechanisms of enhanced macrophage-mediated prostaglandin E2 production and its suppressive role in Th1 activation in Th2-dominant BALB/c mice. J Immunol 2003;170: 757-764.
26. Mc Adam BF, Mardini IA, Habib A, Burke A, Lawson JA, Kapoor S, Fitgerald GA. Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J Clin Invest 2000;105:1473-1482.
27. Vane JR, Bakhle YS, Bolting RM. Cyclooxygenase 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
28. Davidge ST. Prostaglandin H synthase and vascular function. Circ Res 2001;89:650-660.
29. Turini ME, DuBois RN. Cyclooxygenase-2: a therapeutic target. Annu Rev Med 2002;53:35-57.
30. Kreuzer J, Denger S, Jahn L, Bader J, Ritter K, von Hodenberg E, Kubler W. LDL stimulates chemotaxis of human monocytes through a cyclooxygenase- dependent pathway. Arterioscler Thromb Vasc Biol 1996;16:1481-1487.
31. Cao HJ, Wang HS, Zhang Y, Lin HY, Phipps RP, Smith TJ. Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostagalandin endoperoxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-associated ophtalmopathy. J Biol Chem 1998;273:29615-29625.
32. Callejas NA, Casado M, Diaz-Guerra MJ, Bosca L, Martin-Sanz P. Expression of cyclooxygenase-2 promotes the release of matrix metalloproteinase-2 and -9 in fetal rat hepatocytes. Hepotology 2001;33:860-867.
33. Shankavaram UT, Lai WC, Netzel-Arnett S, Mangan PR, Ardans JA, Caterina N, Stetler-Stevenson WG, Birkedal-Handsen H, Wahl LM. Monocyte membrane type. 1-matrix metalloproteinase. Prostaglandin-dependent regulation and role in metalloproteinase-2 activation. J Biol Chem 2001;276:19027-19032.
34. Hernandez-Presa MA, Martin-Ventura JL, Ortego M, Gomez-Hernandez A, Tunon J, Hernandez-Vargas P, Blanco-Colio LM, Mas S, Aparicio C, Ortega L, Vivanco F, Gerique JG, Diaz C, Hernandez G, Egido J. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured smooth muscle cells. Atherosclerosis 2002;160:49-58.
35. Cipollone F, Fazia M, Iezzi A, Zucchelli M, Pini B, De Cesare D, Ucchino S, Spigonardo F, Bajocchi G, Bei R, Muraro R, Artese L, Piattelli A, Chiarelli F, Cuccurullo F, Mezzetti A. Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation 2003;107:1479-1485.
36. Chenevard R, Hurlimann D, Bechir M, Enseleit F, Spieker L, Hermann M, Riesen W, Gay S, Gay RE, Neidhart M, Michel B, Luscher TF, Noll G, Ruschitzka F. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003;107:405-409.
37. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-959.
38. Pitt B, Pepine C, Willerson JT. Cyclooxygenase-2 inhibition and cardiovascular events. Circulation 2002;106:167-169.
39. Blake GJ, Ridker PM. Novel clinical markers of vascular inflammation. Circ Res 2002;89:763-771.
40. Papafili A, Hill MR, Brull DJ, McAnulty, Marshall RP, Humphries SE, Laurent GJ. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 2002;22: 1631-1636.
41. Cipollone F, Patrono C. Cyclooxygenase-2 polymorphism. Putting a brake on the inflammation response to vascular injury? Arterioscler Thromb Vasc Biol 2002;22:1516-1518.